Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.

Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.

Leukemia. 2018 Mar 29. doi: 10.1038/s41375-018-0116-y. [Epub ahead of print]

PMID:
29749396
2.

Constraints on signaling network logic reveal functional subgraphs on Multiple Myeloma OMIC data.

Miannay B, Minvielle S, Magrangeas F, Guziolowski C.

BMC Syst Biol. 2018 Mar 21;12(Suppl 3):32. doi: 10.1186/s12918-018-0551-4.

3.

Logic programming reveals alteration of key transcription factors in multiple myeloma.

Miannay B, Minvielle S, Roux O, Drouin P, Avet-Loiseau H, Guérin-Charbonnel C, Gouraud W, Attal M, Facon T, Munshi NC, Moreau P, Campion L, Magrangeas F, Guziolowski C.

Sci Rep. 2017 Aug 23;7(1):9257. doi: 10.1038/s41598-017-09378-9.

4.

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

Magrangeas F, Kuiper R, Avet-Loiseau H, Gouraud W, Guérin-Charbonnel C, Ferrer L, Aussem A, Elghazel H, Suhard J, Sakissian H, Attal M, C Munshi N, Sonneveld P, Dumontet C, Moreau P, van Duin M, Campion L, Minvielle S.

Clin Cancer Res. 2016 Sep 1;22(17):4350-4355. doi: 10.1158/1078-0432.CCR-15-3163. Epub 2016 Apr 8.

5.

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L, Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H.

Blood. 2015 Dec 17;126(25):2713-9. doi: 10.1182/blood-2015-06-650242. Epub 2015 Oct 29.

6.

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC.

Clin Cancer Res. 2015 Oct 15;21(20):4607-18. doi: 10.1158/1078-0432.CCR-15-0200. Epub 2015 May 15.

7.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien ML, Hulin C, Leleu X, Yon E, Marit G, Karlin L, Roussel M, Stoppa AM, Belhadj K, Voillat L, Garderet L, Macro M, Caillot D, Mohty M, Facon T, Moreau P, Attal M, Munshi N, Corre J, Minvielle S, Avet-Loiseau H.

Blood. 2015 Mar 26;125(13):2095-100. doi: 10.1182/blood-2014-07-587964. Epub 2015 Jan 30.

8.

Differential and limited expression of mutant alleles in multiple myeloma.

Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas MA, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC.

Blood. 2014 Nov 13;124(20):3110-7. doi: 10.1182/blood-2014-04-569327. Epub 2014 Sep 18.

9.

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.

Amin SB, Yip WK, Minvielle S, Broyl A, Li Y, Hanlon B, Swanson D, Shah PK, Moreau P, van der Holt B, van Duin M, Magrangeas F, Pieter Sonneveld P, Anderson KC, Li C, Avet-Loiseau H, Munshi NC.

Leukemia. 2014 Nov;28(11):2229-34. doi: 10.1038/leu.2014.140. Epub 2014 Apr 15.

10.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC.

Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.

11.

The shaping and functional consequences of the dosage effect landscape in multiple myeloma.

Samur MK, Shah PK, Wang X, Minvielle S, Magrangeas F, Avet-Loiseau H, Munshi NC, Li C.

BMC Genomics. 2013 Oct 2;14:672. doi: 10.1186/1471-2164-14-672.

12.

Cereblon expression in multiple myeloma: not ready for prime time.

Lodé L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F, Minvielle S, Pellat-Deceunynck C, Bene MC, Moreau P.

Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17. No abstract available.

PMID:
23862718
13.

Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles.

Li Y, Wang X, Zheng H, Wang C, Minvielle S, Magrangeas F, Avet-Loiseau H, Shah PK, Zhang Y, Munshi NC, Li C.

PLoS One. 2013;8(3):e58809. doi: 10.1371/journal.pone.0058809. Epub 2013 Mar 15.

14.

Minor clone provides a reservoir for relapse in multiple myeloma.

Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, Garderet L, Voillat L, Facon T, Stoppa AM, Marit G, Hulin C, Casassus P, Tiab M, Voog E, Randriamalala E, Anderson KC, Moreau P, Munshi NC, Minvielle S.

Leukemia. 2013 Feb;27(2):473-81. doi: 10.1038/leu.2012.226. Epub 2012 Aug 9.

15.

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P.

J Clin Oncol. 2012 Jun 1;30(16):1949-52. doi: 10.1200/JCO.2011.36.5726. Epub 2012 Apr 30.

PMID:
22547600
16.

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.

Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, Magrangeas F, Goldschmidt H, Morgan GJ, Avet-Loiseau H.

Haematologica. 2011 Nov;96(11):1728-32. doi: 10.3324/haematol.2011.041434. Epub 2011 Jul 26.

17.

Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients.

Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S.

Blood. 2011 Jul 21;118(3):675-8. doi: 10.1182/blood-2011-03-344069. Epub 2011 May 31.

18.

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, Decaux O, Lamy T, Legros L, Fuzibet JG, Michallet M, Corront B, Lenain P, Hulin C, Mathiot C, Attal M, Facon T, Harousseau JL, Minvielle S, Moreau P; Intergroupe Francophone du Myélome.

Blood. 2011 Feb 10;117(6):2009-11. doi: 10.1182/blood-2010-07-295105. Epub 2010 Oct 20.

19.

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.

Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S, Avet-Loiseau H.

Haematologica. 2010 Nov;95(11):1973-6. doi: 10.3324/haematol.2010.023697. Epub 2010 Jul 15.

20.

Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity.

Decaux O, Clément M, Magrangeas F, Gouraud W, Charbonnel C, Campion L, Loiseau HA, Minvielle S.

Cancer Sci. 2010 Apr;101(4):889-97. doi: 10.1111/j.1349-7006.2009.01467.x. Epub 2009 Dec 11.

21.

Prognostic significance of copy-number alterations in multiple myeloma.

Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, Moreau P, Anderson KC, Campion L, Munshi NC, Minvielle S.

J Clin Oncol. 2009 Sep 20;27(27):4585-90. doi: 10.1200/JCO.2008.20.6136. Epub 2009 Aug 17.

22.

A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.

Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L.

Breast Cancer Res Treat. 2009 Aug;116(3):509-20. doi: 10.1007/s10549-008-0250-8. Epub 2008 Nov 20.

PMID:
19020972
23.

Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S; Intergroupe Francophone du Myélome.

J Clin Oncol. 2008 Oct 10;26(29):4798-805. doi: 10.1200/JCO.2007.13.8545. Epub 2008 Jun 30.

PMID:
18591550
24.

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen.

Campone M, Campion L, Roché H, Gouraud W, Charbonnel C, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Jézéquel P.

Breast Cancer Res Treat. 2008 Jun;109(3):491-501. Epub 2007 Jul 21.

PMID:
17659439
25.

CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.

Robillard N, Wuillème S, Lodé L, Magrangeas F, Minvielle S, Avet-Loiseau H.

Leukemia. 2005 Nov;19(11):2021-2. No abstract available.

PMID:
16167057
26.

Genetic heterogeneity in multiple myeloma.

Magrangeas F, Lodé L, Wuilleme S, Minvielle S, Avet-Loiseau H.

Leukemia. 2005 Feb;19(2):191-4. Review.

PMID:
15538406
27.

Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma.

Wuilleme S, Robillard N, Lodé L, Magrangeas F, Beris H, Harousseau JL, Proffitt J, Minvielle S, Avet-Loiseau H; Intergroupe Francophone de Myélome.

Leukemia. 2005 Feb;19(2):275-8.

PMID:
15538401
28.

[Manufacture of DNA chips in a laboratory for internal use: legislation and quality assurance].

Jézéquel P, Pichon J, Magrangeas F, Minvielle S, Millour M, Ricolleau G, Malvaux S.

Ann Biol Clin (Paris). 2004 May-Jun;62(3):361-6. French.

29.

Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.

Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, Harousseau JL, Bataille R, Minvielle S, Avet-Loiseau H.

Blood. 2004 May 15;103(10):3869-75. Epub 2004 Jan 8.

30.

Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.

Thieblemont C, Nasser V, Felman P, Leroy K, Gazzo S, Callet-Bauchu E, Loriod B, Granjeaud S, Gaulard P, Haioun C, Traverse-Glehen A, Baseggio L, Bertucci F, Birnbaum D, Magrangeas F, Minvielle S, Avet-Loiseau H, Salles G, Coiffier B, Berger F, Houlgatte R.

Blood. 2004 Apr 1;103(7):2727-37. Epub 2003 Nov 20.

31.

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.

Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Houlgatte R, Minvielle S.

Blood. 2003 Jun 15;101(12):4998-5006. Epub 2003 Mar 6.

32.

14q32 chromosomal translocations: a hallmark of plasma cell dyscrasias?

Avet-Loiseau H, Minvielle S, Mellerin MP, Magrangeas F, Bataille R.

Hematol J. 2000;1(5):292-4. No abstract available.

PMID:
11920205
33.

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R; Intergroupe Francophone du Myélome.

Blood. 2002 Mar 15;99(6):2185-91.

34.

Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.

Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R; Intergroupe Francophone du Myélome.

Blood. 2001 Nov 15;98(10):3082-6.

35.

Negative regulation of onconstatin M signaling by suppressor of cytokine signaling (SOCS-3).

Magrangeas F, Boisteau O, Denis S, Jacques Y, Minvielle S.

Eur Cytokine Netw. 2001 Apr-Jun;12(2):309-15.

36.

Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3).

Magrangeas F, Boisteau O, Denis S, Jacques Y, Minvielle S.

Biochem J. 2001 Jan 15;353(Pt 2):223-30.

37.

Cloning and expression of CIS6, chromosome assignment to 3p22 and 2p21 by in situ hybridization.

Magrangeas F, Apiou F, Denis S, Weidle U, Jacques Y, Minvielle S.

Cytogenet Cell Genet. 2000;88(1-2):78-81.

PMID:
10773671
38.

Natural splicing of exon 2 of human interleukin-15 receptor alpha-chain mRNA results in a shortened form with a distinct pattern of expression.

Dubois S, Magrangeas F, Lehours P, Raher S, Bernard J, Boisteau O, Leroy S, Minvielle S, Godard A, Jacques Y.

J Biol Chem. 1999 Sep 17;274(38):26978-84.

39.

Cotranscription and intergenic splicing of human galactose-1-phosphate uridylyltransferase and interleukin-11 receptor alpha-chain genes generate a fusion mRNA in normal cells. Implication for the production of multidomain proteins during evolution.

Magrangeas F, Pitiot G, Dubois S, Bragado-Nilsson E, Chérel M, Jobert S, Lebeau B, Boisteau O, Lethé B, Mallet J, Jacques Y, Minvielle S.

J Biol Chem. 1998 Jun 26;273(26):16005-10.

Supplemental Content

Loading ...
Support Center